IL10 and prostate carcinoma: Clinical grade isolation of the cDC2 subset is now possible, and the utility of these cells as an autologous vaccine is under clinical investigation in prostate cancer and malignant melanoma.22,30 The capacity to produce IL-12 to support Th1-dependent CTL responses is an important feature of cDC2 cells.28,31 When cDC2 were isolated from patients (n = 6) and healthy controls they secreted heterogeneous amounts of IL-10 and IL-12 (Figure 3).